Schizophrenia/Psychosis

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Facing limited resources, cultural barriers, and complex mental health cases, A newly qualified doctor’s year in rural South Africa offers a deep dive into psychiatry in underserved areas.

Digital therapeutics may help improve negative symptoms associated with schizophrenia.

Although iclepertin was found to be well tolerated, the agent did not meet endpoints.

What is the appropriate duration for antipsychotic use and how can you safely taper or discontinue them?

Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.

Perhaps, in our modern arguments over the reality of mental illness, we are merely reinventing the wheel—or maybe, just spinning our wheels.

An FDA committee recently decided the clozapine REMS protocol was no longer necessary. How will this impact clinicians?

A recent longitudinal, retrospective study aimed to examine antipsychotic prescribing and rehospitalization rates in a forensic psychiatric sample.

Researchers investigated the link between psychosis, criminal sanctions, and mortality rates following discharge from a hospital for acute psychosis.

Negative symptoms pose significant challenges for individuals with schizophrenia and their caregivers.

Psychiatry: one of the most dynamic and rapidly evolving specialties in medicine.

New research links reduced synaptic density,early psychosis, and cannabis use, offering insights into negative symptoms and potential interventions.

The presentation of catatonia can vary, making its management challenging, particularly in resource-limited settings in South Africa.

Let's look back on a year marked by advancements and ongoing challenges in psychiatry.

Learn more about best practices when treating comorbid trauma and psychosis.

In a new study, researchers found the subtype of childhood trauma impacts the effectiveness of antipsychotic medications.

What does the clozapine REMS recommendations from the FDA Advisory Committees mean for clinical care?

Gordon Lavigne, MEd, CEO of the Schizophrenia & Psychosis Action Alliance, talk about the joint FDA committee's vote on clozapine REMS.

Calling it a barrier to care, FDA committees decide to end clozapine REMS.

How is the study of muscarinic receptors transforming schizophrenia treatment?

How can you best discuss long-acting injectable options with your patients living with schizophrenia?

Traumatic life events are common among individuals who experience psychosis. Here's how best to assess and treat.

Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.

The medication treatment of schizophrenia has finally diversified to a novel neurotransmitter system: the muscarinic cholinergic system.